Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Mylan Inc. : Before the Bell Scans of MYL, TEVA, COV, VRX, and ZTS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2013 | 08:50am CEST

StockCall.com Provides Stock Research on Mylan Inc., Teva Pharmaceutical Industries Ltd, Covidien plc, Valeant Pharmaceuticals International Inc., and Zoetis Inc.

New York City, New York -- (May 09, 2013)

Equity markets edged higher on Wednesday after struggling initially. It was yet another historic day as the Dow Jones and the S&P 500 closed at fresh all-time high levels. Market sentiment was lifted by better-than-expected trade data from China. Improving global economic outlook coupled with ultra-loose monetary policies from developed world central banks have boosted investors? risk appetite. Yesterday, the healthcare sector was among the best performers in the S&P 500. Among the major movers in this sector were Mylan Inc. (NASDAQ: MYL), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Covidien Plc (NYSE: COV), Vertex Pharmaceuticals International Inc. (NYSE: VRX), and Zoetis Inc. (NYSE: ZTS). StockCall has taken an interest in these companies and you can now sign up to download the free technical research on MYL, TEVA, COV, VRX, and ZTS at

www.stockcall.com/registration

Mylan Inc.?s shares edged lower in trading on Wednesday. The stock traded between $29.30 and $29.93 before finishing the day 1.21% lower at $29.33 on volume of 4.41 million. Despite the losses yesterday, Mylan?s shares have gained nearly 1.50% in the last three trading sessions. Year-to-date, the stock has gained more than 6.80%, underperforming the broad market. Shares of MYL are currently trading more than 6% below their 52-week high. Sign up today to read the free research report on MYL at

www.StockCall.com/MYL050913.pdf

Shares of Teva Pharmaceutical Industries Ltd. edged higher in yesterday?s trading session; however, the gains were limited. The stock closed 0.18% higher at $38.42 on volume of 2.94 million. Teva Pharmaceutical?s shares are currently trading close to their 52-week low of $38.33. The stock is also trading below its 50-day and 200-day moving averages which is a bearish signal. However, the stock?s MACD has just crossed above the signal line which suggests that market sentiment has turned bearish. Register to download the free technical analysis on TEVA at

www.StockCall.com/TEVA050913.pdf

Shares of Covidien Plc edged higher on Wednesday, tracking gains in the broad market. The stock touched an intraday high of $65.88 before finishing the day 0.98% higher at $65.88 on volume of 2.89 million. Covidien?s shares have gained nearly 2.40% in the last three trading sessions. The stock has seen a series of highs over the past week which is a bullish signal. The positive trend is further confirmed by recent volume activity, and the stock?s MACD chart. Free report on COV can be accessed by registering at

www.StockCall.com/COV050913.pdf

Valeant Pharmaceuticals International Inc.?s shares struggled in yesterday?s trading session. The stock ended the day 0.28% lower at $73.86 on volume of 713,719. The company?s shares are currently trading close to their 52-week high of $76.57. The stock has gained nearly 23.60% so far in 2013 as compared to a gain of nearly 14.50% for the S&P 500. The stock is currently trading above its 50-day and 200-day moving averages.Register withStockCall and download the research on VRX for free at

www.StockCall.com/VRX050913.pdf

Shares of Zoetis Inc. rose in trading on Wednesday. The stock touched an intra-day high of $33.44 before finishing the day 1.16% higher at $33.26 on volume of 1.03 million. Zoetis?shares have underperformed the S&P 500 so far in 2013, gaining nearly 7.50%. The stock?s MACD is currently trading above the signal line and the zero-line which is a bullish signal. Shares of ZTS are trading nearly 6% below their 52-week high. Read the full free research on ZTS by signing up to StockCall at

www.StockCall.com/ZTS050913.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

www.stockcall.com

Contact Person:

William T. Knight

Email: [email protected]

Contact Number: (646) 396-9857 (9:00 am EST ? 01:30 pm EST)


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MYLAN INC
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
05/17 MYLAN : Theravance Biopharma and Mylan to Present Additional Data for Revefenaci..
05/16 MYLAN : to Present at UBS Global Healthcare Conference
05/16 MYLAN : Honors National Women's Health Week to Empower Women to Take Control of ..
05/11 GSK escapes Advair hit for now as second generic bid fails
05/10DJMARKET SNAPSHOT : Nasdaq Closes At Record For 4th Straight Day As Dow Slips In F..
05/10DJMARKET SNAPSHOT : Stock Market Flat As Investors Digest Trump's Firing Of FBI's ..
05/10 Mylan says disagrees with FDA over generic Advair delay
05/10DJMARKET SNAPSHOT : Stock Market Falls After Trump's Firing Of FBI's Comey Raises ..
05/10 MYLAN NV : Investor Network: Mylan N.V. to Host Earnings Call
More news
Sector news : Pharmaceuticals - NEC
03:18p Cross-border M&A between U.S. and European firms at 10 year high
08:32aDJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
05/19 European shares claw back gains after worst week in six months
05/19 FTSE climbs for fourth straight week, shrugging off Trump slump
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Financials ($)
Sales 2017 12 502 M
EBIT 2017 3 725 M
Net income 2017 2 086 M
Debt 2017 12 843 M
Yield 2017 -
P/E ratio 2017 13,75
P/E ratio 2018 12,53
EV / Sales 2017 2,65x
EV / Sales 2018 2,39x
Capitalization 20 334 M
More Financials
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 49,0 $
Spread / Average Target 29%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%20 334
JOHNSON & JOHNSON10.23%342 117
ROCHE HOLDING LTD.14.79%235 098
NOVARTIS AG6.28%210 347
PFIZER INC.-0.06%193 303
MERCK & CO., INC.8.34%174 449
More Results